CAS No.: 1001404-83-6
AAI-101 is a novel extended-spectrum β-lactamase inhibitor with activity against many β-lactamases, including some class A and class D carbapenemases
Packing | Price | Stock | Quantity |
---|---|---|---|
100 mg | Get quote | ||
250 mg | Get quote | ||
1 g | Get quote |
E-mail: sales@hmobio.com
Tech Support: services@hmobio.com
AAI-101 is a novel extended-spectrum β-lactamase inhibitor with activity against many β-lactamases, including some class A and class D carbapenemases; is currently in clinical development as a combination with cefepime, reduces the MIC50 of cefepime against a collection of 223 cefepime-nonsusceptible isolates of the family Enterobacteriaceae from >64 mg/L to 0.125 mg/L.
1. Crandon JL, et al. Antimicrob Agents Chemother. 2015 May;59(5):2688-94.
2. Crandon JL, et al. Pathogens. 2015 Aug 18;4(3):620-5.
M.Wt | 314.32 | |
Formula | C11H14N4O5S | |
CAS No. | 1001404-83-6 | |
Storage |
|
|
Chemical Name/SMILES | (2S,3S,5R)-3-methyl-3-((1-methyl-1H-1,2,3-triazol-3-ium-3-yl)methyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide |
086-18516630705
sales@hmobio.com
1/F, building 4, No. 358-368, Kefu Road, Jiading District, Shanghai, China